Page 13 - Sun Pharma
Sun Pharma, Britain's AstraZeneca join to distribute cancer drugs in China
The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed
 "Sun Pharma, Britain's AstraZeneca join to distribute cancer drugs in China")
Specialty drugs essential for re-rating of Sun Pharma stock, say analysts
Analysts say, Tuesday's launch of ophthalmic specialty product Cequa can achieve peak sales of $100-125 million per annum
 "Specialty drugs essential for re-rating of Sun Pharma stock, say analysts")
Sun Pharmaceutical launches Cequa to treat dry eye disease in US market
Cequa is indicated to increase tear production in patients with dry eye, Sun Pharma said
 "Sun Pharmaceutical launches Cequa to treat dry eye disease in US market")
Symptoms of success
Soma Das has been able to capture brilliantly the essence of Dilip Shanghvi through countless stories
 "Symptoms of success")
Sun Pharma slides 4% after Co says forensic audit by Sebi underway
A forensic audit has been ordered by Sebi w.r.t. the financial statements of the company for the financial years ending FY16, FY17, and FY18.
 "Sun Pharma slides 4% after Co says forensic audit by Sebi underway")
Sebi orders forensic audit of Sun Pharma financial statements from FY16-18
Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit
 "Sebi orders forensic audit of Sun Pharma financial statements from FY16-18")
Sun Pharma slides 4% on report of Sebi ordering forensic audit
The audit has been ordered based on allegations of corporate governance and tax-related offences and securities market-related violations by the company
Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud
HDFC Securities has 'buy' rating on Sun Pharma with a 12-month target price of Rs 545 as the brokerage expects a recovery in the profitability (24 per cent margin) by FY21E.
 "Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud")
Sebi inquiry clears Sun Pharma, finds no merit in allegations of fraud
The investigation team is of the view that the matter does not require further probe, said sources. The team sent its report to the Sebi committee for vetting
Sun Pharmaceutical's US specialty ramp-up still slow, say experts
Sun's focus on specialty comes at a time when its US revenues are under pressure owing to competitive intensity
 "Sun Pharmaceutical's US specialty ramp-up still slow, say experts")
Sun Pharma announces tie-up for China foray; to develop 8 generic products
The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China
Sun Pharma signs global licensing pact with CSIR-IICT for patents
The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications
Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results
Glenmark Pharmaceuticals plunged 9 per cent, while Dr Reddy's slipped 8 per cent in intra-day trade
 "Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results")
Global business growth, lower costs a booster dose for Sun Pharma
Company focusing on specialty portfolio to drive US growth
 "Global business growth, lower costs a booster dose for Sun Pharma")
Sun Pharma Q1 net rises 31% to Rs 1,387 crore on lower R&D expenses
India's largest drugmaker has raised focus on specialty and limited competition products in the wake of pricing pressure in the US
 "Sun Pharma Q1 net rises 31% to Rs 1,387 crore on lower R&D expenses")
Sun Pharma net profit up 31% at Rs 1,387 cr in June quarter of FY20
The company had posted a profit of Rs 1,057.29 crore for the corresponding period of the previous fiscal, Sun Pharma said in a filing to BSE
Nilesh Gupta to Dilip Shanghvi, most pharma CEOs took a pay cut in FY19
The CEOs' salaries also have taken a brunt. A quick analysis shows that Shanghvi took a whopping 99 per cent pay cut
 "Nilesh Gupta to Dilip Shanghvi, most pharma CEOs took a pay cut in FY19")
Sun Pharma shuts two clinical units in Vadodara for cost efficiency
Drug major Sun Pharma on Saturday said it is discontinuing operations at two clinical pharmacology units in Vadodara (Gujarat) to bring in efficiencies in cost and processes. "While we continue to make investments in our R&D operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes," a Sun Pharmaceutical Industries spokesperson said in a statement. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, the company is discontinuing operations at two centers at Tandalja and Akota in Vadodara, the spokesperson added. "The bio-equivalence studies from these centers will be transferred to our other facilities. We are offering full support to the affected employees and helping them with out placement services," the spokesperson said. As per industry sources, the move would impact around 80 staffers at the two locations. Sun Pharma has six major R&D centers ..
 "Sun Pharma shuts two clinical units in Vadodara for cost efficiency")
Sun Pharma shuts down two R&D units in Vadodara; lays off some employees
Market sources peg the number at 85 personnel who have been terminated and given three months salary in advance
Dilip Shanghvi takes 99% pay cut despite Sun Pharma's 27% earnings growth
Shanghvi, one of the lowest-paid CEOs in India's pharmaceutical sector, drew a salary of Rs 1 during 2018-19
 "Dilip Shanghvi takes 99% pay cut despite Sun Pharma's 27% earnings growth")
